Clinicians should strongly consider prescribing or co-prescribing naloxone to certain patients at risk for opioid overdose, and educating them about its use, according to guidance released today by the Department of Health and Human Services. For example, the recommendation includes patients prescribed opioids who are receiving them at a dosage of 50 morphine milligram equivalents per day or greater; have respiratory conditions such as chronic obstructive pulmonary disease or obstructive sleep apnea; have been prescribed benzodiazepines; or have a substance use disorder, excessive alcohol use or mental health disorder. “This new guidance reflects our commitment to ensuring those who need overdose-reversing drugs have them and provides practical steps that clinicians, patients, and the public can take to reduce the risk of an overdose,” said HHS Secretary Alex Azar.

Related News Articles

Headline
The Food and Drug Administration July 31 announced that it is requiring safety label changes to all opioid pain medications to further emphasize and explain…
Headline
The AHA released a new toolkit to improve continuity of care for patients with opioid and stimulant use disorders. Developed with support from the Centers for…
Headline
The Substance Abuse and Mental Health Services Administration July 28 released its latest national survey on drug use and mental health. Among the findings,…
Headline
The U.S. Department of Health and Human Services July 10 rescinded a policy that extended certain federal public benefits to immigrants lacking permanent legal…
Headline
The House June 4 passed the AHA-supported SUPPORT Act (H.R. 2483) by a 366-57 vote. The legislation reauthorizes key prevention, treatment and recovery…
Headline
Overdose deaths in the U.S. fell 26.9% last year to 80,391, according to estimates from the Centers for Disease Control and Prevention. The agency reported…